{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T12:20:55Z","timestamp":1793535655357,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Global Services, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and treatment-free intervals, and increased rates of toxicities and comorbidities. Here, we examine frontline treatment patterns, and attrition rates by LOT among newly diagnosed MM (NDMM) patients in the United States who were eligible or ineligible for autologous stem cell transplant (ASCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were identified from three US patient-level databases collectively covering the period January 2000 to September 2018. Patients had an index diagnosis of MM on or after January 1, 2007, medical and prescription insurance coverage at diagnosis, a 1-year look-back period prior to the index diagnosis, no prior malignancies in the 1-year period before index diagnosis, and had received \u22651 LOT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among patients who did not receive ASCT (non-transplant;\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200922,062), 12,557 (57%) received only 1 LOT and 9505 (43%) received &gt;\u20091 LOT. Patients receiving only 1 LOT were significantly older, had higher mean Charlson Comorbidity Index (CCI) scores, and higher incidences of comorbidities. Among the 2763 patients receiving ASCT, 2184 received &gt;\u20091 LOT, and 579 (21%) received only 1 LOT (ie, ASCT was the last treatment). 1682 (61%) patients received induction therapy as frontline treatment, of whom 187 (11%) also received consolidation therapy. The latter group was younger than those who received only induction therapy, had lower mean CCI scores, and comparable or lower incidences of selected comorbidities. The most common frontline therapy for non-transplant and transplant-eligible patients was bortezomib\/dexamethasone and bortezomib\/lenalidomide\/dexamethasone, respectively. Attrition rates across all LOTs were high for non-transplant patients (range, 43\u201357%) and transplant patients (range, 21\u201337%). Treatment duration decreased by LOT for non-transplant patients and was consistent across LOTs for transplant patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this analysis, a substantial proportion of patients with NDMM who received frontline therapy did not appear to receive a subsequent LOT. These high attrition rates underscore the need to use the most optimal treatment regimens upfront rather than reserving them for later LOTs in which the clinical benefit may decrease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07503-y","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T08:09:58Z","timestamp":1604995798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma"],"prefix":"10.1186","volume":"20","author":[{"given":"Rafael","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneesha","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Slavcev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Ukropec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Maiese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"7503_CR1","unstructured":"SEER Cancer Stat Facts: Myeloma. Bethesda: National Cancer Institute. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 24 Feb 2020."},{"issue":"14","key":"7503_CR2","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228\u201363.","journal-title":"J Clin Oncol"},{"issue":"suppl_4","key":"7503_CR3","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv52\u201361.","journal-title":"Ann Oncol"},{"issue":"2","key":"7503_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91\u20137.","journal-title":"N Engl J Med"},{"issue":"19","key":"7503_CR5","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875\u201383.","journal-title":"N Engl J Med"},{"issue":"2","key":"7503_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252\u201364.","journal-title":"Br J Haematol"},{"issue":"4","key":"7503_CR7","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/10428194.2017.1361035","volume":"59","author":"JP MacEwan","year":"2018","unstructured":"MacEwan JP, Batt K, Yin W, Peneva D, Sison S, Vine S, et al. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. Leuk Lymphoma. 2018;59(4):941\u20139.","journal-title":"Leuk Lymphoma"},{"key":"7503_CR8","doi-asserted-by":"publisher","first-page":"e13026","DOI":"10.1111\/ecc.13026","volume":"28","author":"L Antunes","year":"2019","unstructured":"Antunes L, Rocha-Goncalves F, Chacim S, Lefevre C, Pereira M, Pereira S, et al. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal. Eur J Cancer Care (Engl). 2019;28:e13026.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"7503_CR9","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","volume":"19","author":"N Despi\u00e9gel","year":"2019","unstructured":"Despi\u00e9gel N, Touboul C, Flinois A, Saba G, Suzan F, Gonzalez-McQuire S, et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France. Clin Lymphoma Myeloma Leuk. 2019;19(1):e13\u201328.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"6","key":"7503_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"7503_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175(1):66\u201376.","journal-title":"Br J Haematol"},{"issue":"5","key":"7503_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/13696998.2017.1421546","volume":"21","author":"S Gonzalez-McQuire","year":"2018","unstructured":"Gonzalez-McQuire S, Yong K, Leleu H, Mennini FS, Flinois A, Gazzola C, et al. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. J Med Econ. 2018;21(5):450\u201367.","journal-title":"J Med Econ"},{"key":"7503_CR13","volume-title":"NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma Version 2","author":"National Comprehensive Cancer Network","year":"2019","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma Version 2. 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed 24 Feb 2020."},{"key":"7503_CR14","unstructured":"Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18(10):e401\u201319."},{"key":"7503_CR15","doi-asserted-by":"crossref","unstructured":"Moehler TM, Merz M, Kellermann L, Goldschmidt H, Knauf W. Diagnostic and therapeutic approaches to multiple myeloma patients: \u2018real-world\u2019 data from representative multicentre treatment surveys in Germany between 2008 and 2011. Oncol Lett. 2016;12(6):5043\u201351.","DOI":"10.3892\/ol.2016.5375"},{"key":"7503_CR16","doi-asserted-by":"crossref","unstructured":"Hajek R, Jarkovsky J, Maisnar V, Pour L, Spicka I, Minarik J, et al. Real-world outcomes of multiple myeloma: retrospective analysis of the Czech registry of monoclonal gammopathies. Clin Lymphoma Myeloma Leuk. 2018;18(6):e219\u201340.","DOI":"10.1016\/j.clml.2018.04.003"},{"key":"7503_CR17","doi-asserted-by":"crossref","unstructured":"Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R, et al. Analysis of real-world data on overall survival in multiple myeloma patients with >\/=3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21(11):1355\u201361.","DOI":"10.1634\/theoncologist.2016-0104"},{"issue":"2","key":"7503_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/cam4.576","volume":"5","author":"TW Flaig","year":"2016","unstructured":"Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016;5(2):182\u201391.","journal-title":"Cancer Med"},{"issue":"10","key":"7503_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076882","volume":"8","author":"N Kubitz","year":"2013","unstructured":"Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One. 2013;8(10):e76882.","journal-title":"PLoS One"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07503-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07503-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07503-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T08:11:25Z","timestamp":1604995885000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07503-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7503"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07503-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"10 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As the databases used contain only retrospective data, and since patients are not identifiable, approval and written informed consent by patients or Institutional Review Board\/Independent Ethical Committee approvals are not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Rafael Fonseca served as a consultant for AbbVie, Aduro, Amgen, Bayer, BMS\/Celgene, GlaxoSmithKline, Janssen, Juno, Kite, Merck, Novartis, Oncotracker, Pharmacyclics, and Sanofi; and participated in an advisory board for Adaptive Biotechnologies. Saad Z. Usmani served as a consultant\/advisor for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, SkylineDx, and Takeda; participated in a Speakers Bureau for Amgen, Celgene, Janssen, Sanofi, and Takeda; and received research grants from Amgen, Array Biopharma, Bristol-Myers Squibb, Celgene, Janssen, Merck, Pharmacyclics, Sanofi, and Takeda. Maneesha Mehra, Mary Slavcev, Jianming He, Sarah Cote, Annette Lam, Jon Ukropec, and Sandhya Nair are employees of Janssen. Eric M. Maiese was an employee of Janssen at the time the study was conducted. Ravi Potluri is an employee of SmartAnalyst Inc. Peter M. Voorhees received research funding from Amgen, Celgene, GlaxoSmithKline, Janssen, and Takeda; and served as a consultant\/advisor for Adaptive Biotechnologies, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Oncopeptides, Takeda, and TeneBio.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1087"}}